Comparator bias: why comparisons must address genuine uncertainties

Mann, Howard; Djulbegovic, Benjamin
January 2013
JRSM Cardiovascular Disease;Jan2013, Vol. 106 Issue 1, p30
Academic Journal
The article discusses the problem of comparator bias in controlled clinical trials. It is noted that comparator bias is introduced when treatments known to be beneficial are withheld from patients participating in controlled trials. The article also discusses the inappropriate use of inactive comparators and several ways to reduce comparator bias.


Related Articles

  • Planning a clinical research study. Chan, Simon; Jönsson, Anders; Bhandari, Mohit // Indian Journal of Orthopaedics;Jan-Mar2007, Vol. 41 Issue 1, p16 

    The article focuses on randomized controlled trials (RCT) as the most valid of the clinical research designs. It says that the randomization process involves generation of an allocation sequence and allocation concealment. It stresses that blinding guarantees that performance bias and detection...

  • Clinical trials in India: Where do we stand globally? Selvarajan, Sandhiya; George, Melvin; S., Suresh Kumar; Dkhar, Steven Aibor // Perspectives in Clinical Research;Jul-Sep2013, Vol. 4 Issue 3, p160 

    Aims: To evaluate the trend of clinical trials in India over the last 4 years compared to the well-established countries using clinical trial registries since the advent of clinical trial registry of India (CTRI). Materials and Methods: The data of clinical trials registered in India, United...

  • Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Claudia Castañeda; Natividad Neri; Sergio Cleto; Alejandra Talavera; Martha González; Judith Huerta-Guzmán; M. Nambo // Medical Oncology;Sep2008, Vol. 25 Issue 3, p360 

    Abstract  We performed a controlled clinical trial to define the use of a brief therapy: CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone) compared with standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of peripheral T-cell...

  • Obstacles to researching the researchers: A case study of the ethical challenges of undertaking methodological research investigating the reporting of randomised controlled trials. McKenzie, Joanne E.; Herbison, G. Peter; Roth, Paul; Paul, Charlotte // Trials;2010, Vol. 11, p28 

    Background: Recent cohort studies of randomised controlled trials have provided evidence of within-study selective reporting bias; where statistically significant outcomes are more likely to be more completely reported compared to non-significant outcomes. Bias resulting from selective reporting...

  • A Hercule Poirot of clinical research. Sakamoto, Junichi // Gastric Cancer;Jan2016, Vol. 19 Issue 1, p21 

    The author comments on the lack of oversight of randomized clinical trials which has occasionally led to investigator misconduct. Topics covered include the failure to standardize rules for the conduct of post-marketing trials, a case of data fabrication in Japan disclosed by a whistleblower in...

  • The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. Tharmanathan, Puvan; Calvert, Melanie; Hampton, John; Freemantle, Nick // BMC Medical Research Methodology;2008, Vol. 8, Special section p1 

    Background: Interim analysis of accumulating trial data is important to protect participant safety during randomized controlled trials (RCTs). Data Monitoring Committees (DMCs) often undertake such analyses, but their widening role may lead to extended use of interim analysis or recommendations...

  • Subjective endpoints in clinical trials: the case for blinded independent central review. Walovitch, Richard; Bin Yao; Chokron, Patrick; Helen Le; Bubley, Glenn // Open Access Journal of Clinical Trials;2013, Vol. 5, p111 

    Primary efficacy and safety endpoints in clinical trials are often subjective assessments made by site personnel. For international confirmatory trials conducted over broad geographic regions and different clinical practice settings, variability in these subjective assessments can be...

  • CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Boutron, Isabelle; Altman, Douglas G.; Moher, David; Schulz, Kenneth F.; Ravaud, Philippe // Annals of Internal Medicine;7/4/2017, Vol. 167 Issue 1, p40 

    Incomplete and inadequate reporting is an avoidable waste that reduces the usefulness of research. The CONSORT (Consolidated Standards of Reporting Trials) Statement is an evidence-based reporting guideline that aims to improve research transparency and reduce waste. In 2008, the CONSORT Group...

  • Good reporting practices and the CONSORT. LIRA, RODRIGO PESSOA CAVALCANTI; ARIETA, CARLOS EDUARDO LEITE // Arquivos Brasileiros de Oftalmologia;2012, Vol. 75 Issue 2, p86 

    The authors discuss the Consolidated Standards of Reporting Trials (CONSORT) statement which provides a 25-item checklist for a minimum set of recommendations for reporting the trial design, analysis and result. First published in 1996 and updated in 2001 and 2010, CONSORT was developed to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics